ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.676,88
1,05%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,0839
-0,13%
Bitcoin
69.153,96
2,07%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. VYNE Therapeutics Inc (VYNE)

  7. VYNE Therapeutics Inc (VYNE) News

VYNE

VYNE Therapeutics (VYNE)

VYNE Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VYNE
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VYNEVYNE Therapeutics Inc
09/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VYNEVYNE Therapeutics Inc
01/03/202423h16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VYNEVYNE Therapeutics Inc
01/03/202423h15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VYNEVYNE Therapeutics Inc
29/02/202414h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VYNEVYNE Therapeutics Inc
02/02/202415h42Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VYNEVYNE Therapeutics Inc
03/01/202423h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
03/01/202423h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
03/01/202423h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
03/01/202423h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
03/01/202423h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
03/01/202423h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
03/01/202423h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
03/01/202414h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VYNEVYNE Therapeutics Inc
15/12/202323h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
15/12/202323h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
15/12/202323h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
15/12/202323h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
15/12/202323h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
13/12/202322h36Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VYNEVYNE Therapeutics Inc
13/12/202322h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VYNEVYNE Therapeutics Inc
04/12/202322h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYNEVYNE Therapeutics Inc
24/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VYNEVYNE Therapeutics Inc
22/11/202322h07Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VYNEVYNE Therapeutics Inc
16/11/202322h30Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VYNEVYNE Therapeutics Inc
13/11/202322h30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VYNEVYNE Therapeutics Inc
13/11/202322h03Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VYNEVYNE Therapeutics Inc
13/11/202322h01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:VYNEVYNE Therapeutics Inc
13/11/202321h59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VYNEVYNE Therapeutics Inc
13/11/202313h57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VYNEVYNE Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VYNE

Kürzlich von Ihnen besucht

NYSE
ALP-Q
Alabama Power
EU
5501T
5501T
BIT
Q00343
Leonteq Securities
BIT
Q00307
Leonteq Securities
BIT
UC2V56
Unicredit Bank
BIT
P10W63
Bnp Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten